The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-α antagonist: A metaanalysis of both randomized controlled trials and registry/cohort studies

Journal of Rheumatology

Volumn 42, Issue 12, 2015, Pages 2229-2237

  Ai, Jing Wen ^a   Zhang, Shu ^a   Ruan, Qiao Ling ^a   Yu, Yi Qi ^a   Zhang, Bing Yan ^a   Liu, Qi Hui ^a   Zhang, Wen Hong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Rheumatoid arthritis; Tuberculosis; Tumor necrosis factor antagonists

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ARTICLE; COHORT ANALYSIS; HUMAN; INCIDENCE; INFECTION RISK; LATENT TUBERCULOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TUBERCULOSIS; ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMORBIDITY; FEMALE; FOLLOW UP; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MALE; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY; REFERENCE VALUE; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; REGISTRIES; SEVERITY OF ILLNESS INDEX; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84948799016     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150057     Document Type: Article

References (41)

1. Pratt AG, Isaacs JD, Mattey DL. Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009;23:37-48.
2. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-22.
3. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-iv, xi-xiii, 1-229.
4. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
5. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206.
6. Zumla A, George A, Sharma V, Herbert N, Baroness Masham of Ilton. WHO's 2013 global report on tuberculosis: successes, threats, and opportunities. Lancet 2013;382:1765-7.
7. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
8. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
9. Fonseca JE, Canhão H, Silva C, Miguel C, Mediavilla MJ, Teixeira A, et al; Grupo de Estudos de Artrite Reumatóide da Sociedade Portuguesa de Reumatologia. [Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience]. [Article in Portuguese] Acta Reumatol Port 2006;31:247-53.
10. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006;43:717-22.
11. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. [Internet. Accessed September 8, 2015.] Available from: community.cochrane.org/handbook
12. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-75.
13. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92.
14. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
15. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10:1127-32.
16. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-11.
17. Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61.
18. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al; B S R B R Control Centre Consortium, BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.
19. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60:1884-94.
20. Tam LS, Leung CC, Ying SK, Lee GK, Yim CW, Leung YY, et al. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong-the role of TNF blockers in an area of high tuberculosis burden. Clin Exp Rheumatol 2010;28:679-85.
21. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013;72:37-42.
22. Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012;12:225-9.
23. Yoo IK, Choung RS, Hyun JJ, Kim SY, Jung SW, Koo JS, et al. Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy. Yonsei Med J 2014;55:442-8.
24. Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J, et al. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis 2015;74:1212-7.
25. Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009;8:266-73.
26. Health Protection Agency. Tuberculosis in the UK. Annual report on tuberculosis surveillance and control in the UK 2008. [Internet. Accessed September 8, 2015.] Available from: webarchive. national-archives.gov.uk/20140714084352/http://www.hpa.org.uk/Publications/InfectiousDiseases/Tuberculosis/0810Tuberculosis intheUK/
27. Cabases JM, Villalbi JR, Aibar C. [2002 SESPAS report: investing in health. Priorities for public health in Spain]. [Website in Spanish] [Internet. Accessed September 8, 2015.] Available from: www.sespas.es/ind-lib06.html
28. Centre for Health Protection, Department of Health Hong Kong, China. Notification & death rate of tuberculosis (all forms), 1947-2014. [Internet. Accessed September 8, 2015.] Available from: www.chp.gov.hk/en/data/4/10/26/43/88.html
29. Antoine D, Che D. [Cases of tuberculosis disease declared in France in 2006]. [Article in French] [Internet. Accessed September 8, 2015] Available from: www.researchgate.net/publication/237794608-Les-cas-de-tuberculose-maladie-dclars-en-France-en-2006
30. Centers for Disease Control and Prevention (CDC). 2001 Annual summary: summary of notifiable diseases. [Internet. Accessed August 19, 2015.] Available from: www.cdc.gov/nchstp/tb/surv/surv2001/default.htm
31. Korean National Tuberculosis Association. [Trend of case notification rate per 100000 by year, 2004-2011]. [Website in Korean] [Internet. Accessed August 19, 2015] Available from: www.knta.or.kr
32. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al; START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86.
33. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology 2014;53:1872-85.
34. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49:1-51.
35. Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001;166:6728-34.
36. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731-40.
37. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1-20.
38. To KW, Reino JJ, Yoo DH, Tam LS. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective. Respirology 2013;18:765-73.
39. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010;10:308-15.
40. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008;58:1248-57.
41. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstrom DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012;7:e30275.